Hodgkin's Disease Clinical Trial
Official title:
Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High Grade
Predicting response to chemotherapy in patients with Hodgkin's disease or lymphoma
high-grade malignant de novo or recurrence.
The non-Hodgkin's lymphoma and high-grade Hodgkin's disease may show resistance to
chemotherapy, regardless of their initial extension. The failure of treatment is most often
correlated with an incomplete answer or lack of response to chemotherapy as a result
chemoresistance. This drug, which may involve the gene MDR1 (multidrug resistance) encoding
the protein PGP, can be studied in vivo by MIBI scan. The MIBI is behind a tracer
perfusionnel used routinely to explore myocardial perfusion, but it has other
characteristics of fixing, which can be used in oncological imaging (fixation by glial
tumors of high grade).Prospective Study, which includes conducting a tomoscintigraphie 30
minutes after injection of 20 mCi of 99mTc-MIBI in initial stock or relapse of high-grade
lymphoma and Hodgkin's disease any stage (I-IV). Fixing the MIBI is compared with
morphological abnormalities detected by CT and the setting of lesions by 18FDG. Patients
will be treated in a traditional way, without changes in treatment protocols used in
routine. Patients with a negative MIBI scan, will be watched with particular attention in
order to detect insufficient response to chemotherapy. The only change, the care of
patients, only for the achievement of an initial consideration of non-invasive imaging,
further, which is the tomoscintigraphie the MIBI. Of the tumor samples, will be evaluated by
immunohistochemistry, the expression of PGP and the MRP1 (two proteins associated with the
drug). On blood, may be carried out genotyping of MDR1, MRP1 and MRP2 to the patient.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01665768 -
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
|
Phase 2 | |
| Completed |
NCT01188798 -
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 3 | |
| Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
| Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
| Completed |
NCT00150462 -
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
|
Phase 1 | |
| Completed |
NCT02856646 -
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
|
||
| Completed |
NCT01458288 -
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
|
Phase 2 | |
| Completed |
NCT00990587 -
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
|
Phase 1 | |
| Terminated |
NCT00594308 -
In-Vivo Activated T-Cell Depletion to Prevent GVHD
|
N/A | |
| Completed |
NCT00469729 -
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
|
Phase 2/Phase 3 | |
| Completed |
NCT00552825 -
Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children
|
N/A | |
| Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
| Completed |
NCT00165438 -
Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy
|
N/A | |
| Recruiting |
NCT02007811 -
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
|
Phase 1/Phase 2 | |
| Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00569842 -
Investigation of the Cylex® ImmuKnow® Assay
|
N/A | |
| Completed |
NCT00665314 -
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
|
Phase 2 | |
| Completed |
NCT00256191 -
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00284804 -
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
|
Phase 2 | |
| Completed |
NCT00396201 -
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
|
Phase 2 |